The tension between menthol's switching advantage and its youth appeal is at the heart of the FDA's regulatory calculus. The agency's JUUL2 authorization represents a specific choice: the adult benefit outweighs the youth risk, for this specific product, with these specific access-control features (age-gated app, device lock, Pod ID authentication).

But this is a product-by-product determination. The FDA has stated that PMTAs are reviewed on a case-by-case basis, and the JUUL2 reasoning does not automatically transfer to other menthol products or to flavors beyond menthol.

The broader policy question is whether regulators can build frameworks that capture menthol's switching benefit for adults while minimizing youth access. Canada's experience suggests that blunt flavor bans may be counterproductive — pushing smokers back to cigarettes. The JUUL2's technology features (age verification, device locking) represent one possible answer, but their real-world effectiveness remains to be demonstrated.

What is clear from the evidence: the most important variable is not flavor. It is whether the smoker switches completely. Any policy or product that facilitates complete switching — regardless of flavor — is likely to produce greater public health benefit than one that doesn't.